Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biocon Takes Its Oncology Biosimilars To 30 Countries In Africa And Asia

Enables Access To Trastuzumab And Pegfilgrastim Through Cancer Access Partnership

Executive Summary

Indian company Biocon is aiming to “deliver substantial savings to healthcare systems” by enhancing access to and availability of oncology biosimilars in 25 countries in Africa and five countries in Asia, covered under the Cancer Access Partnership, led by the Clinton Health Access Initiative.

You may also be interested in...



Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea

Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron

Biocon Biologics CEO Makes Surprise Exit

The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.

Biocon Pledges To Cut Insulin Prices

India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”

Topics

UsernamePublicRestriction

Register

GB150645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel